Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis
- 1 January 2010
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 298 (1) , G126-G132
Abstract
Statin has antifibrotic efficacy in human fibrosing diseases, such as pulmonary and renal fibrosis, and is therefore implicated in hepatic fibrosis. However, statin can also activate protein kinase C (PKC), which augments hepatic fibrogenesis and is thereby likely to reduce the antifibrotic efficacy of statin. This study was designed to explore the hypothesis that simultaneous treatment with statin and PKC inhibitor may synergistically enhance antifibrotic efficacy in hepatic fibrosis. Hepatic fibrosis models were established in BALB/c mice by intraperitoneal injection of carbon tetrachloride or thioacetamide for 6 wk. Pravastatin and enzastaurin (PKC inhibitor) were administered by gavage for 5 wk. Cellular apoptosis was explored using 4′,6-diamidino-2-phenylindole or terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick end-labeling (TUNEL) staining and immunoblot analysis. Hepatic fibrosis and hepatic stellate cell (HSC) activation were assessed by morphometric analysis of histological findings and immunohistochemistry for α-smooth muscle actin. In vitro, the addition of PKC inhibitor significantly increased statin-induced LX-2 cell apoptosis by enhancing the activation of mitochondrial apoptotic signals. TUNEL-positive HSCs were significantly increased in mice treated with statin + PKC inhibitor compared with those in control or single compound-treated mice. The percentage of area occupied by activated HSCs and the extent of collagen deposition were significantly decreased in mice treated with statin + PKC inhibitor compared with those in control or statin-treated mice. In conclusion, simultaneous treatment with statin and PKC inhibitor synergistically enhanced the antifibrotic efficacy in both in vitro and in vivo models of hepatic fibrosis and may therefore have therapeutic implication for reducing hepatic fibrosis.Keywords
This publication has 34 references indexed in Scilit:
- Heat Shock Protein 90 Inhibitor Induces Apoptosis and Attenuates Activation of Hepatic Stellate CellsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cellsLiver International, 2008
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2007
- Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organJournal of Clinical Investigation, 2007
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatinArthritis & Rheumatism, 2006
- Liver fibrosis – from bench to bedsideJournal of Hepatology, 2003
- Leptin is required for fibrogenic responses induced by thioacetamide in the murine liverHepatology, 2002
- Intracellular Signaling Pathways Involved in Acetaldehyde–Induced Collagen and Fibronectin Gene Expression in Human Hepatic Stellate CellsHepatology, 2001